Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-MATCH: Adoptive T Cell Therapy for Recurrent Medulloblastoma and PNET
NCT01326104Phase 2Completed
- Sponsor
- University of Florida
- Start
- Sep 2010
- Primary completion
- Mar 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TTRNA-xALT, TTRNA-DC vaccine in medulloblastoma, primitive neuroectodermal tumor (PNET), sponsored by University of Florida. Started Sep 2010; status: completed.
02
Drugs
TTRNA-xALTTTRNA-DC vaccine
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NCT01326104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326104.